MedPath

Electro-Acupuncture for Obese Patients with Insulin Resistance: a Randomized Sham-Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Obesity
Insulin Resistance
Registration Number
NCT06609200
Lead Sponsor
Nanyang Technological University
Brief Summary

This clinical trial aims to evaluate the efficacy and safety of electro-acupuncture for obese patients with insulin resistance. 60 participants will be randomized and allocated to either the electro-acupuncture arm or the sham acupuncture arm.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria

men and women aged between 21 and 65 years old; BMI ≥ 25 kg/m2; HOMA-IR ≥ 2.14, (HOMA-IR = fasting insulin (ųU/mL)* fasting glucose (mmol/L)/22.5); not receiving any other weight control measures or any medical and/or drug history in the last 3 months.

Exclusion Criteria

diabetes mellitus; treatment with drugs that may affect insulin sensitivity; changes >10% of usual body weight in the previous 6 months weight; endocrine diseases, including thyroid disorder, pituitary disorder, sex gland disorder, etc.; heart diseases, including arrhythmia, heart failure, and myocardial infarction, participants with pacemakers; allergy and immunology diseases; bleeding tendency; pregnant or lactating women; impaired hepatic or renal function; stroke or unable to exercise.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
HOMA-IRFrom enrollment to the end of follow up at 16 weeks

HOMA-IR = fasting insulin (ųU/mL)\* fasting glucose (mmol/L)/22.5

Secondary Outcome Measures
NameTimeMethod
Body Mass Index (BMI)From enrollment to the end of follow up at 16 weeks

BMI = kg/m2

Waist-to-hip ratioFrom enrollment to the end of follow up at 16 weeks

The waist-hip ratio or waist-to-hip ratio (WHR) is the dimensionless ratio of the circumference of the waist to that of the hips.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.